• This first GWAS meta-analysis on lung function decline conducted separately in 206 non-asthmatic and asthmatic cohort participants suggests that genetic 207 determinants of lung function decline are different in the two groups. 208
• The results further suggest that previously identified genetic determinants of 209 cross-sectional lung function are not major determinants of the decline. 210 211 212
Capsule summary: 213
This meta-analysis provides evidence for genetic heterogeneity of lung function 214 between asthmatics and non-asthmatics; and between cross-sectionally and 215 longitudinally measured lung function. Low lung function is a feature of both asthma and chronic obstructive pulmonary 241 disease (COPD), with twin studies demonstrating strong heritability (0.51 to 0.77) for 242 forced expiratory volume in the first second (FEV1) 1, 2 . The two respiratory diseases and 243 lung function itself share predisposing and phenotypic features, including increased 244 airway responsiveness and atopy as well as exogenous risk factors 3, 4 . Genome-wide 245 association studies (GWAS) have identified novel genetic loci for asthma [5] [6] [7] [8] [9] [10] 246 and lung function [15] [16] [17] [18] and provide the opportunity to study agnostically their overlap in 247 genetic background 19 . Some of the implicated genes, such as PDE4D, support a link 248 between asthma and COPD which may be rooted in shared pathways during lung 249 development 20 . However, the majority of the genes implicated in asthma or COPD 250 GWAS analyses have not been identified as top association signals in GWAS for lung 251 function in the general population [15] [16] [17] [18] , with the exception of HHIP and FAM13A being 252 associated with both lung function [15] [16] [17] [18] . Several lines of evidence suggest 253 that different genes influence lung function in asthmatics and in non-asthmatics. 254
Genome-scans in family based linkage studies identified some, but overall limited 255 overlap between chromosomal regions linked to lung function in asthmatics 21 , COPD 256 patients 22 and in the general population 23 and it has been suggested that genetic 257 variation may be more important for lung function in asthma after adjusting for smoking 258 and body size differences 21, 24, 25 . 259
Here, we present results from the first lung function GWAS conducted separately for 260 asthmatics and non-asthmatics. This current study also focuses on the rate of lung 261 function decline in adults instead of cross-sectional lung function parameters tested in 262 previous GWAS [15] [16] [17] [18] . The discovery cohorts included two population-based studies 263 (SAPALDIA and ECRHS) and one asthma family-based study (EGEA), all of European 264 ancestry with highly comparable and standardized assessment of respiratory health 265 parameters including spirometry from two time points ten years apart. These three 266 studies had been included in the GWAS for asthma conducted by the GABRIEL 267 consortium 7 . Replication cohorts included three population-based cohorts (FHS, ARIC, 268 B58C) and one family-based asthma study (the Dutch Asthma Study). 269
METHODS

270
-Discovery cohorts and study population: Three large multi-centric cohorts EGEA 26 were obtained [26] [27] [28] [29] . No bronchodilator was administered. Based on questionnaire data, 286 asthmatics were defined as asthma self-report at any of the completed surveys and 287 family-based studies considered additional clinical asthma criteria (see online 288 repository). Genotyping for discovery cohorts was centrally performed on the Illumina 289
Human 610quad BeadChip at the Centre National de Génotypage (CNG, Evry, 290 France) 7 . Imputation of genotypes based on Hapmap2 reference panel, investigation of 291 population stratification and quality control criteria are described in Figure EI and Table  292 EI in the Online Repository. 293 -Replication Cohorts: Four cohorts of European ancestry with available genome-wide 294 data, ARIC 30 , FHS 15 ; B58C 31 ; Dutch asthma study 32 were used for replication. Subjects 295 included in the current analysis were older than 24 years, had complete information on 296 covariates (age, height, and sex) and valid lung function measures from at least two 297 time-points. The lung function measurements were conducted at least ten years apart, 298 except three years apart for ARIC (Table I) were derived from sex-specific linear regression models adjusted for age, height and 304 study centre in asthmatics and non-asthmatics separately. Comparability between 305 studies of standardized residuals was tested using Wilcoxon-Mann-Whitney test 306 (P>0.94). The standardized residuals were used as dependent variable and regressed 307 on genome-wide single nucleotide polymorphisms (SNPs) adjusted for study-specific 308 principal components capturing population ancestry (see online supplement for details). 309
Study-specific SNP effect estimates were combined through meta-analysis using fixed 310 and random effects models. We used a threshold of P<5x10 -8 (the Bonferroni 311 adjustment for one million independent tests) to declare a pooled effect as genome-312 wide significant. Selection criteria for replication loci are described in the methods 313 section of the online repository. SNPs with suggestive evidence of association with 314 decline in FEV1 or FEV1/FVC were chosen for in silico replication (Table EIII, 
Online 315
Repository). Study-specific regression models and meta-analyses across replication 316 cohorts were as described for the discovery phase. Replication cohorts with spirometry 317 data from more than two different time points modelled the lung function decline 318 phenotype by fitting a least-squares slope using the available data (FHS, Dutch asthma 319 study). P≤0.05 was considered as statistically significant at the replication level. 320
The results of the main meta-analyses for the top 1000 SNPs are available in the online 321 repository (Table EIV A to D, Online Repository). We also conducted a meta-analysis by 322 combining non-asthmatic and asthmatic samples and tested for heterogeneity between 323 these samples (Table EV , Online Repository). Additional sensitivity analyses were done 324 by: a) restricting the GWAS sample to subjects aged 30 and older for FEV1 decline 325 (Table EIV E (Table EIV G 
to J, Online 327
Repository); c) investigating smoking stratified joint effects for replications SNPs (Table  328 EVI, Online Repository); d) excluding ARIC, a cohort having substantially shorter follow-329 up time that the other cohorts (three years instead of ten years) from replication 330 analyses (Table EVII , Online Repository). Methods and results of these additional 331 analyses are described in the online repository. 332
RESULTS 334
Characteristics of the study populations 335
The cohorts included in this study differed by age and type of recruitment, and 336 accordingly in lung function and the proportion of subjects with FEV1/FVC below 70% 337 (Table I, Table EVIII , Online Repository). Baseline lung function parameters, but not 338 their annual changes were lower in asthmatics when compared to non-asthmatics in 339 each study. The proportion of never smokers was comparable among asthmatics, but 340 varied among non-asthmatics (ranging from 28.5% in B58C to 46.5% in EGEA). No 341 substantial differences in the smoking prevalence between people with and without 342 asthma were observed within each study. Comparing the discovery cohorts in more 343 detail (Table EVIII , Online Repository), atopy (total IgE ≥100kU/ml) and hay fever were 344 more prevalent in both asthmatics and non-asthmatics from EGEA when compared to 345 ECRHS and SAPALDIA. Current asthma was more prevalent (84.4%) in EGEA than in 346 SAPALDIA (25.5%) or ECRHS (43.3%) and the prevalence of a positive family history 347 for asthma was also highest in EGEA, in agreement with the study design. Asthmatics 348 from EGEA had a younger age of disease onset due to the mode of recruitment of the 349 proband. 350
351
Main findings from meta-analyses of discovery and replication phase 352
In the discovery phase, GWAS meta-analysis of decline in FEV1 and FEV1/FVC was 353 conducted in 2677 non-asthmatics and in 1441 asthmatics. Genomic inflation factors 354 were low for both lung function parameters (λ<1.047, Table EIX, Online Repository) 355
suggesting minimal unaccounted population stratification. The replication panel included 356 a total of 10'858 non-asthmatics and 1'138 asthmatics. Thirty lead SNPs belonging to 357 30 loci (5x10 -8 < P discovery <6x10 -5 ) were chosen for replication. 358
The four lung function parameter-and asthma-specific meta-analyses identified one 359 association signal that almost reached the genome-wide significance level (P = 5.3x10 -360 8 ) at the locus 8p22 containing the TUSC3 gene for FEV1/FVC decline in asthmatics 361 while all other signals had P<5x10 -7 ( Figure I ), but this signal was not associated with 362 FEV1/FVC decline in asthmatics in the replication sample. The only locus of the 363 selected replication candidate loci that formally replicated was 13q14.3, containing the 364 DLEU7 gene, associated with decline in FEV1 in the non-asthmatics (P discovery =4.8x10 -6 365 and P replication =0.03). 366
In the global post hoc analysis combining both asthmatics and non-asthmatics 367 (N=4118), a striking finding was the absence of any pronounced association signals (P 368 >1x10 -6 ) despite increased statistical power. This was in agreement with the minimal 369 overlap of association signals observed in asthmatics and non-asthmatics separately. 370
Most signals at P<10 -5 from the asthma-stratified analysis in the discovery phase 371 exhibited statistically significant heterogeneity of effects between the two groups ( Table  372 II). At the replication stage, none of the replication SNPs was associated with lung 373 function decline in asthmatics and non-asthmatics combined. 374 375
Association signals for annual decline in FEV1 in non-asthmatics 376
Of fifteen SNPs associated at P<10 -5 with decline in FEV1 in non-asthmatics ten were 377 (Table II) replicated. The G-allele of SNP rs9316500 near the DLEU7 gene was 382 positively associated with annual FEV1 decline in the discovery cohorts (P=4.8x10 -6 ) 383 and in the replication cohorts (P=0.026). Although heterogeneity between studies was 384 not significant (P=0.61), the combined P value did not reach the genome-wide level 385 (P=5.7x10 -5 ). 386 387
Association signals for annual decline in FEV1 in asthmatics 388
Eighteen SNPs in nine distinct chromosomal locations were associated with decline in 389 FEV1 in asthmatics at P<10 -5 . None of the loci selected for in silico replication was 390 confirmed (Table II) . 391 392
Association signals for annual decline in FEV1/FVC in non-asthmatics 393
Seven loci showed association with FEV1/FVC decline in non-asthmatics at 10 -6 <P<10 -394 5 , but no locus selected for replication was confirmed (Table II) . 395 396
Association signals for annual decline in FEV1/FVC in asthmatics 397
Twelve SNPs at the locus 8p22 containing the gene TUSC3 at 15.68Mb were 398 associated with FEV1/FVC decline at P<10 -7 in asthmatics (Figure I). Regional locus 399 plot and forest plot are presented in the online repository ( Figure EIII) . The top 400 association signals in this locus were conferred by distinct SNPs in each cohort, though 401 apparently they were located in the same putative haplotype segment in SAPALDIA and 402 in EGEA (Figure EIV, Online Repository). There was no statistically significant 403 association in ECRHS. Meta-analysis of the discovery samples identified SNP 404 rs4831760 as top signal in TUSC3 gene, but heterogeneity between discovery studies 405 was borderline significant (P=0.07). The C-allele (P=5.3x10 -8 ) was positively associated 406 with annual decline in FEV1/FVC in asthmatics (Beta=0.22 ±0.04 (standard error); Table  407 II). However this association was not replicated (P=0.80). In the meta-analysis 408 combining discovery and replication samples the resulting P-value for rs4831760 was 409 2.8x10 -5 . All but the Dutch asthma study, exhibited effect estimates in the same 410 direction as the discovery panel. Two other candidate loci (MPP7 and SYNE2) also 411 failed replication testing. 412 413
SNPs previously associated in GWAS meta-analyses on cross-sectional lung function 414
The associations of top hit SNPs from previous GWAS meta-analyses on cross-415 sectional lung function 11, 15-18 and a replication study in asthmatics 33 were assessed 416 separately for asthmatics and non-asthmatics in the discovery cohorts. Associations 417 were assessed for both, lung function parameters of decline (annual decline and 418 percent change) and cross-sectional lung function level. Overall, a subset of variants 419 and loci showed replication of association with cross-sectional lung function in either 420 non-asthmatics or asthmatics. Few of the loci showed strong association with decline in 421 lung function. We present associations at P<0.05 in Table III and those at P≥0.05 in 422 For baseline FEV1, we observed associations for SNPs belonging to 4q24 (GSTCD, 424 rs11731417, P=1.3x10 -4 ) and 15q23 (THSD4, rs1913768, P=0.003). Associations with 425 baseline FEV1 were mainly restricted to non-asthmatics. For baseline FEV1/FVC, 426 associations of SNPs of THSD4 were prominent (e.g. rs12899618, P=3.3x10 -4 ) and 427 again restricted to non-asthmatics. 428
For decline phenotypes of FEV1, we observed associations for SNPs in regions 6p21 429 (DAAM2, 0.003<P<0.02) and 4q28 (HHIP, 0.02<P<0.05) among asthmatics and in 430 THSD4 (0.003<P<0.04) among non-asthmatics. The strongest associations observed 431 for decline phenotypes of FEV1/FVC were two SNPs in MMP15 (16q13, 432 0.003<P<0.002) in non-asthmatics, only. Association in the combined sample of 433 asthmatics and non-asthmatics did not substantially alter the results. 434 435
Summary of findings from sensitivity analyses 436
We observed in non-asthmatics, aged 30 years and more, that MUSK and DLEU7 were 437 no longer prominently associated with FEV1 decline, but SNPs in other genes remained 438 strongly associated (ZIC1, rs6785065, P=2.3x10 -5 ; UBL3, rs278037, P=4.8x10 -5 ). 439
Results of the GWAS on percent change in lung function showed that the FEV1 440 association signal for DLEU7 in the non-asthmatics was no longer significant; however 441 the signals for MUSK (rs1889321, P=2.92x10 -7 ) and other loci remained unaltered 442 (ZIC1, rs6785065, P=2.0x10 -5 ; KIRREL3, rs11604082, P=4.1x10 -6 ; KIAA2117, 443 rs10082549, P=2.7x10 -6 ). Top signals associated with decline in FEV1/FVC in 444 asthmatics remained unaltered for TUSC3 (rs4831760, P=5.2x10 -8 ) and for SYNE2 445 (rs7144584, P=6.4x10 -7 ) after taking baseline lung function into account. 446
Smoking stratified analyses of the replication SNPs revealed no substantial difference in 447 association between ever and never smokers except for a few SNPs belonging to loci 448 containing SYNE2, RORA, BCAS1, or PLXNA4 genes. 449 Replication meta-analysis excluding the ARIC data substantially reduced sample size in 450 non-asthmatics and the association of DLEU7 with decline of FEV1 was no longer 451 significant. Instead two loci for association with decline in FEV1 in asthmatics (PLXNA4, 452 rs10808265, P discovery =1.7x10 -6 , P replication =0.02 and SLC45A3, rs16856186, 453 P discovery =8.9x10 -6 , P replication =0.04) and one locus, FLJ25393, for decline in FEV1/FVC in 454 non-asthmatics (rs2658782, P discovery =4.3x10 -6 , P replication =0.03) gained statistical 455 significance. 456
DISCUSSION 458
A main result of this study is the observed genetic heterogeneity of lung function decline 459 between asthmatics and non-asthmatics. When we combined the two groups in the 460 discovery phase we observed no genome-wide significant association signal despite 461 larger sample size. All top hit association signals detected by the asthma stratified 462 analysis showed significant heterogeneity according to the disease status. In the 463 replication phase, this heterogeneity was also confirmed for the DLEU7 locus which was 464 associated with FEV1 decline in non-asthmatics only. Finally, many of the SNPs 465 identified by previous GWAS on lung function exhibited associations specific to asthma 466 status. 467
468
The finding of genetic heterogeneity in lung function reported here is consistent with 469 available evidence. Differences in familial segregation of FEV1 in asthmatic and non-470 asthmatic families previously suggested genetic heterogeneity between these two 471 groups 24 . Agnostic studies investigating genetic determinants of lung function in both, 472 family-based 21, 22, 34-37 and population-based samples 15-18, 23, 25 produced little overlap in 473 chromosomal regions. Genome-wide scans on lung function in asthma 21, 38 or COPD 22 474 families also suggested a heterogeneous genetic architecture of lung function. 475 476 Nevertheless, some previously reported overlapping linkage regions for the ratio of 477 Consistent with these results, neither asthma, atopy and COPD genes previously 494 identified in large GWAS 5-9, 11 nor genes related to smoking behavior 49 were associated 495 with lung function decline in our study. The association of FEV1 decline with a gene 496 related to height, DLEU7, was ranking high, but only in subjects without asthma 497 (rs9316500, P discovery =4.8x 10 -6 ; P replication =0.03). DLEU7 gene product and expression 498 remain poorly characterized, but its mRNA has been detected in the lung. The DLEU7 499 locus was identified as a determinant of adult height in previous GWAS meta-500 analyses 50-52 . Three other height genes, HHIP, GPR126 and PTCH, were associated 501 with cross-sectional lung function [15] [16] [17] . All of these lung function models including ours 502
were adjusted for adult height. The observed association, related to both HHIP and 503 DLEU7 being associated with peak height velocity in infancy 51 , suggests that aspects 504 beyond adult height influence lung function and possibly its response to non-genetic 505 determinants. Several genes implicated in respiratory diseases indicate that early lung 506 development impacts respiratory health later in life 20 . Sensitivity analyses are supportive 507 for a growth-specific role of DLEU7. The association of genetic variants in DLEU7 with 508 decline in FEV1 disappeared in analyses considering baseline lung function or restricted 509 to subjects above age 30 with no remaining physiologic lung growth. There might be a 510 link between physiologic growth and unregulated cell differentiation as the DLEU7 gene 511 is also a proposed tumor suppressor gene in chronic lymphocytic leukemia [53] [54] [55] . 512
Evidence emerges for a role of DLEU7 in counterbalancing the proliferative impact of 513 NF-kB on various cell types 56 . The potential role of the gene product of TUSC3, a 514 proposed tumor suppressor gene 57 , in lung physiology is discussed in the Online 515
Repository. 516
None of the SNPs identified in GWAS of cross-sectional lung function 15-18 ranked high in 517
this current GWAS on lung function decline. A strong risk factor for accelerated lung 518 function decline in adulthood is cigarette smoking, but our study was too small to assess 519 gene smoking interaction at the GWAS level. We had decided a priori against smoking 520 adjustment as it is not a confounder, and any link between genotype and smoking is 521 likely to be, at least in part, in the same causal pathway (e.g. gene products 522 metabolizing tobacco constituents or influencing smoking behavior). Their identification 523 as determinants of lung function decline is of public health importance. Consistent with 524 previous GWAS on cross-sectional lung function 15-18 , neither the TUSC3 (heterogeneity 525 between ever/never smokers P=0.98) nor other top hit signals were modified by 526 smoking except for SNPs in SYNE2, RORA, BCAS1 and PLXN4. Arguments for 527 biologic plausibility are mentioned in the Online Repository. 528
The strength of the present study is the longitudinal design of all cohorts included. 529
Repeated spirometric assessments within the same subject is thought to capture more 530 precisely exogenous factors and genes leading to accelerated loss of lung function in 531 adulthood 58 . The discovery cohorts shared comparable questionnaire and spirometry 532 protocols and they were specifically designed to investigate environmental and genetic 533 causes of lung function decline and asthma in a standardized way. Each study has two 534 measures of pre-bronchodilator lung function about ten years apart, but clearly our 535 findings would be more robust if further lung function measures were available over an 536 even longer period of follow-up. All discovery cohorts have used the same genotyping 537 platform and stringent quality control criteria have been applied. 538
Sample size is a limitation of this study, and remains a general challenge in lung 539 function studies with a need for high phenotypic comparability as spirometry results are 540 sensitive to technicians and devices used 59 . The pre-bronchodilation lung function 541 measurements in our and previous lung function GWAS do not allow to differentiate 542 reversible from non-reversible obstruction to airflow. Populations included in this study 543 differed by age which is also reflected by the diverging proportion of subjects with 544 FEV1/FVC <0.7 at follow-up between the discovery cohorts. Discovery and replication 545 populations also differ by time spacing between the spirometry assessments. We can 546 only speculate of on the overall impact of such differences. We do note that replication 547 results were sensitive to the exclusion of ARIC data (the study with highest mean age, 548 largest annual decline, and shortest follow-up time). 549
Other limitations are shared with any GWAS meta-analyses investigating complex 550 phenotypes such as lack in power for investigating gene-environment interactions or 551 studying subgroups of diseases. As the sample size of our study was comparatively 552 small, especially for the asthmatic sample in the replication phase, we had limited ability 553 to address differences in asthma sub-phenotypes or the impact of asthma medication 554 intake. It is also likely that a substantial part of complex disease may be explained by 555 rare mutations not considered by current GWAS. Finally, assessing the joint effect of 556 SNPs having small effects individually and potentially interacting with each other 557 remains another challenge. 558
559
In conclusion, this first GWAS meta-analysis on lung function decline provides 560 suggestive evidence for genetic heterogeneity between persons with and without 561 asthma and between cross-sectionally and longitudinally measured lung function. 562
Consistent with cross-sectional GWAS, our results are also suggestive of height related 563 genes playing a role. Further studies in this area would be enhanced by greater 564 comparability of age range, spacing of lung function assessments, and asthma sub-565 phenotypes (including treatment) to decrease phenotypic heterogeneity and therefore 566 increase statistical power to detect true association candidate loci 60 . Table EXI . 829 rs2304488, rs12447804; MTMR3: rs17646919; NCR3: rs2857595; NOTCH4: rs206015; 853 ONECUT1: rs2456526; PID1: rs1435867, rs1358443, rs3845823; PTCH1: rs10512249, 854 rs576594; RARB: rs1529672; SPATA9: rs153916; TGFB2: rs993925; THSD4: 855 rs12899618; THSD4: rs1568010, rs1913768; TNS1: rs918949, rs1035672, rs929937; 856 ZKSCAN3: rs6903823. Non-significant associations reported in online repository. 857 † Baseline cross-sectional lung function was calculated using Quanjer formula 61 . 858 ‡Proxies tested for cross-sectional association (r 2 , D'): for rs12447804 -rs2304488 859 (0.87, 1); for rs12477314 -rs4521068 (1, 1); for rs2865531 -rs12917651 (1, 1). 860 
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